---
figid: PMC9360236__ajcr0012-2966-f3
pmcid: PMC9360236
image_filename: ajcr0012-2966-f3.jpg
figure_link: /pmc/articles/PMC9360236/figure/fig03/
number: Figure 3
figure_title: ''
caption: 'Diagnostic values of ITGB1-DT expression level in NSCLC as determined using
  ROC analysis. A. NSCLC; B. LUAD; C. LUSC. Note: NSCLC, non-small cell lung cancer;
  LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; ROC, Receiver Operating
  Curve.'
article_title: Interfering with ITGB1-DT expression delays cancer progression and
  promotes cell sensitivity of NSCLC to cisplatin by inhibiting the MAPK/ERK pathway.
citation: Dan Li, et al. Am J Cancer Res. 2022;12(7):2966-2988.
year: '2022'

doi: ''
journal_title: American Journal of Cancer Research
journal_nlm_ta: Am J Cancer Res
publisher_name: e-Century Publishing Corporation

keywords:
- ITGB1-DT
- MAPK
- NSCLC
- overall survival
- disease-specific survival
- progression-free interval

---
